BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 34039308)

  • 1. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
    Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX
    BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulated expression of
    Li D; Ji Y; Guo J; Guo Q
    Future Oncol; 2021 Aug; 17(24):3187-3201. PubMed ID: 34156259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma.
    Li MX; Zhang MY; Dong HH; Li AJ; Teng HF; Liu AL; Xu N; Qu YQ
    Int J Med Sci; 2021; 18(2):494-504. PubMed ID: 33390818
    [No Abstract]   [Full Text] [Related]  

  • 4. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
    Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
    Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    Jiang H; Xu S; Chen C
    BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
    Liu J; Yang X; Zhang L; Yang B; Rao W; Li M; Dai N; Yang Y; Qian C; Zhang L; Xiao H; Wang D
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2299-2310. PubMed ID: 32556504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma.
    Shi YX; Zhu T; Zou T; Zhuo W; Chen YX; Huang MS; Zheng W; Wang CJ; Li X; Mao XY; Zhang W; Zhou HH; Yin JY; Liu ZQ
    Oncotarget; 2016 Dec; 7(51):85235-85243. PubMed ID: 27835911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.
    Li S; Li H; Cao Y; Geng H; Ren F; Li K; Dai C; Li N
    Medicine (Baltimore); 2021 Aug; 100(32):e26474. PubMed ID: 34397869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.
    Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X
    Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Expression of
    Deng H; Huang Y; Wang L; Chen M
    Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
    Zhang J; Sun G; Mei X
    Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
    Chen A; Ding S; Shen X; Lin X
    Comput Math Methods Med; 2021; 2021():9932088. PubMed ID: 34367321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
    Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
    Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
    Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
    Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.